中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
25期
20-21
,共2页
紫杉醇%三维适形放疗%非小细胞肺癌
紫杉醇%三維適形放療%非小細胞肺癌
자삼순%삼유괄형방료%비소세포폐암
Paclitaxel%Three dimensional conformal radiation therapy (3D-CRT)%Non-small cell lung cancer
目的分析临床应用紫杉醇联合三维适形放疗(3D-CRT)治疗局部晚期非小细胞肺癌的应用价值。方法选取2009年11月至2011年3月我院收治的106例局部晚期非小细胞肺癌患者,按随机数字表法随机分为对照组和观察组各53例,对照组给予三维适形放疗,观察组在对照组治疗的基础上给予紫杉醇联合治疗,分析两组患者治疗后的临床疗效。结果治疗完成后观察组PD患者较对照组明显减少,而治疗有效率较对照组明显升高(P<0.05);两组患者不良反应发生率比较无明显差异(P>0.05),无统计学意义。结论临床应用紫杉醇联合三维适形放疗治疗局部晚期非小细胞肺癌能获得良好的治疗效果,且不会产生明显的不良反应,可作为治疗局部晚期非小细胞肺癌的首选方法。
目的分析臨床應用紫杉醇聯閤三維適形放療(3D-CRT)治療跼部晚期非小細胞肺癌的應用價值。方法選取2009年11月至2011年3月我院收治的106例跼部晚期非小細胞肺癌患者,按隨機數字錶法隨機分為對照組和觀察組各53例,對照組給予三維適形放療,觀察組在對照組治療的基礎上給予紫杉醇聯閤治療,分析兩組患者治療後的臨床療效。結果治療完成後觀察組PD患者較對照組明顯減少,而治療有效率較對照組明顯升高(P<0.05);兩組患者不良反應髮生率比較無明顯差異(P>0.05),無統計學意義。結論臨床應用紫杉醇聯閤三維適形放療治療跼部晚期非小細胞肺癌能穫得良好的治療效果,且不會產生明顯的不良反應,可作為治療跼部晚期非小細胞肺癌的首選方法。
목적분석림상응용자삼순연합삼유괄형방료(3D-CRT)치료국부만기비소세포폐암적응용개치。방법선취2009년11월지2011년3월아원수치적106례국부만기비소세포폐암환자,안수궤수자표법수궤분위대조조화관찰조각53례,대조조급여삼유괄형방료,관찰조재대조조치료적기출상급여자삼순연합치료,분석량조환자치료후적림상료효。결과치료완성후관찰조PD환자교대조조명현감소,이치료유효솔교대조조명현승고(P<0.05);량조환자불량반응발생솔비교무명현차이(P>0.05),무통계학의의。결론림상응용자삼순연합삼유괄형방료치료국부만기비소세포폐암능획득량호적치료효과,차불회산생명현적불량반응,가작위치료국부만기비소세포폐암적수선방법。
Objective To evaluate the clinical efficacy of Paclitaxel combined with three dimensional conformal radiation therapy (3D-CRT) on local advanced non-small cell lung cancer. Methods 106 cases of local advanced non-small cell lung cancer, treated in our hospital over November, 2009 to March, 2011, were randomly assigned to control group or observation group according to random number table. Each group was consisted of 53 cases respectively. 3D-CRT alone were performed on each case in control group, meanwhile paclitaxel combined with 3D-CRT were applied on patients in observation group. The therapeutic effects were analyzed in both two groups after treatment. Results The Progression disease (PD) and overall response rate (ORR) were signiifcantly improved in observation group than in control group (P<0.05).The difference of occurrence rate of adverse reaction were not signiifcant between the two groups (P>0.05). Conclusion Paclitaxel combined with 3D-CRT had favorable clinical efifcacy and less adverse reactions. This regime had the potential to become the ifrst line treatment on local advanced non-small cell lung cancer.